MEF2C enhances dopaminergic neuron differentiation of human embryonic stem cells in a parkinsonian rat model.
Human embryonic stem cells (hESCs) can potentially differentiate into any cell type, including dopaminergic neurons to treat Parkinson's disease (PD), but hyperproliferation and tumor formation must be avoided. Accordingly, we use myocyte enhancer factor 2C (MEF2C) as a neurogenic and anti-apop...
Enregistré dans:
Auteurs principaux: | Eun-Gyung Cho, Jeffrey D Zaremba, Scott R McKercher, Maria Talantova, Shichun Tu, Eliezer Masliah, Shing Fai Chan, Nobuki Nakanishi, Alexey Terskikh, Stuart A Lipton |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/53ba5c9a0de04197981d40a27e5ed34c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
par: Shichun Tu, et autres
Publié: (2017) -
Dopaminergic Modulation of Spectral and Spatial Characteristics of Parkinsonian Subthalamic Nucleus Beta Bursts
par: Matthias Sure, et autres
Publié: (2021) -
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
par: Junqiang Yan, et autres
Publié: (2011) -
Predicted transmembrane proteins with homology to Mef(A) are not responsible for complementing mef(A) deletion in the mef(A)–msr(D) macrolide efflux system in Streptococcus pneumoniae
par: Valeria Fox, et autres
Publié: (2021) -
Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients.
par: Judith A Potashkin, et autres
Publié: (2012)